These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9565330)

  • 1. Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy.
    Gornati R; Bembi B; Tong X; Boscolo R; Berra B
    Clin Chim Acta; 1998 Mar; 271(2):151-61. PubMed ID: 9565330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW; Brady RO; Dambrosia JM; Di Bisceglie AM; Doppelt SH; Hill SC; Mankin HJ; Murray GJ; Parker RI; Argoff CE
    N Engl J Med; 1991 May; 324(21):1464-70. PubMed ID: 2023606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI; Giraldo P; Giralt M
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
    Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Gaucher's disease.
    Sidransky E; Martin B; Ginns EI
    N Engl J Med; 1993 May; 328(21):1566; author reply 1567. PubMed ID: 8479500
    [No Abstract]   [Full Text] [Related]  

  • 7. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
    Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.
    Altarescu G; Hill S; Wiggs E; Jeffries N; Kreps C; Parker CC; Brady RO; Barton NW; Schiffmann R
    J Pediatr; 2001 Apr; 138(4):539-47. PubMed ID: 11295718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH
    Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic targets in Gaucher's disease].
    Giraldo P; Roca M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
    J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular basis of treatment in Gaucher's disease].
    Pocoví M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological features in Gaucher's disease during enzyme replacement therapy.
    Ono H; Fujiwara M; Ito K; Ueda H; Mizoguchi N; Sakura N
    Acta Paediatr; 2001 Feb; 90(2):229-31. PubMed ID: 11236058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G; Tylki-Szymanska A; Czartoryska B
    Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
    MacKenzie JJ; Amato D; Clarke JT
    CMAJ; 1998 Nov; 159(10):1273-8. PubMed ID: 9861225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S; Bruno G; Durighello M; Giorgini R; Simeone R; Bembi B
    Haematologica; 1999 Apr; 84(4):376-7. PubMed ID: 10190956
    [No Abstract]   [Full Text] [Related]  

  • 18. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.
    Deibener J; Kaminsky P; Jacob C; Dousset B; Klein M; Duc M
    Haematologica; 1998 May; 83(5):479-80. PubMed ID: 9658738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A; Elstein D; Levy-Lahad E; Zevin S; Hadas-Halpern I; Bar-Ziv Y; Foldes J; Schwartz AJ; Abrahamov A
    Lancet; 1995 Jun; 345(8963):1479-80. PubMed ID: 7769903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.
    Damiano AM; Pastores GM; Ware JE
    Qual Life Res; 1998 Jul; 7(5):373-86. PubMed ID: 9691718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.